Xiaopeng Li

Yantai, 264005, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Engineered oncolytic herpes simplex virus expressing interleukin 12 suppresses tumorigenicity of hepatocellular carcinoma.

Engineered oncolytic herpes simplex virus expressing interleukin 12 suppresses tumorigenicity of hepatocellular carcinoma.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: August 27, 2024

The anti-tumor efficacy of a recombinant oncolytic herpes simplex virus mediated CRISPR/Cas9 delivery targeting in HPV16-positive cervical cancer.

The anti-tumor efficacy of a recombinant oncolytic herpes simplex virus mediated CRISPR/Cas9 delivery targeting in HPV16-positive cervical cancer.

Journal: Antiviral research

Published: June 18, 2024

Influence of tumor mycobiome on cancer pathogenesis (Review).

Influence of tumor mycobiome on cancer pathogenesis (Review).

Journal: Oncology letters

Published: March 17, 2023

Identification of a novel heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) ligand that disrupts HnRNPA2B1/nucleic acid interactions to inhibit the MDMX-p53 axis in gastric cancer.

Identification of a novel heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) ligand that disrupts HnRNPA2B1/nucleic acid interactions to inhibit the MDMX-p53 axis in gastric cancer.

Journal: Pharmacological research

Published: December 14, 2022

Retroperitoneal hemorrhage caused by rupture of superior mesenteric artery: A case report.

Retroperitoneal hemorrhage caused by rupture of superior mesenteric artery: A case report.

Journal: Asian journal of surgery

Published: April 01, 2022

The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy.

The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy.

Journal: Translational oncology

Published: November 11, 2021

VE-822, a novel DNA Holliday junction stabilizer, inhibits homologous recombination repair and triggers DNA damage response in osteogenic sarcomas.

VE-822, a novel DNA Holliday junction stabilizer, inhibits homologous recombination repair and triggers DNA damage response in osteogenic sarcomas.

Journal: Biochemical pharmacology

Published: June 30, 2021

The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.

The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.

Journal: Immunology letters

Published: April 29, 2021

Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody.

Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody.

Journal: Cancer letters

Published: April 11, 2021

Discovery of a novel 53BP1 inhibitor through AlphaScreen-based high-throughput screening.

Discovery of a novel 53BP1 inhibitor through AlphaScreen-based high-throughput screening.

Journal: Bioorganic & medicinal chemistry

Published: November 29, 2020

Recent Advances in the Semisynthesis, Modifications and Biological Activities of Ocotillol-Type Triterpenoids.

Recent Advances in the Semisynthesis, Modifications and Biological Activities of Ocotillol-Type Triterpenoids.

Journal: Molecules (Basel, Switzerland)

Published: October 25, 2020

Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.

Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.

Journal: International journal of immunopathology and pharmacology

Published: September 23, 2020

Showing 1-12 of 12

Last Updated: 09/26/2026